Immunocore Launches Campaign to Educate Physicians on Rare Eye Cancer

(Oxfordshire, UK and Pennsylvania and Maryland, US, 13 May 2019) Uveal melanoma (UM) is a rare and aggressive form of cancer with a poor prognosis once it spreads beyond the eye. Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, has launched, a comprehensive resource to aid physicians on the front line in detecting and managing the disease.